AIHTA - Publications - Search - Items where Division is "Austrian Institute for Health Technology Assessment (AIHTA)" and Year is [pin missing: value2]
  • Institutions (1033)
    • Austrian Institute for Health Technology Assessment (AIHTA) (86)
Number of items at this level: 86.

AIHTA, HTA Austria (2021): Annual Report 2020.

Böhler, C.E.H. and Wolf, S. (2020): Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II). HTA-Projektbericht 132b.

Erdos, J. and Formoso, G. and Djuric, O. and Bonvicini, L. and Pezzarossi, A. and Ballini, L. and Jeroncic, A. (2021): Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia – German Summary of the EUnetHTA OCTA27 Assessment. Decision Support Document 129.

Gassner, L. (2021): Implantation of Bulking Agents for Faecal Incontinence. Update 2021. Decision Support Document 87/1.

Gassner, L. and Mayer-Ferbas, J. (2020): Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia. HTA-Projektbericht 133.

Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.

Geiger-Gritsch, S. and Absenger, G. and Endel, F. and Flicker, M. and Hermann, A. and Kocher, F. and Olschewski, H. and Pall, G. and Wurm, M. and Zechmeister, M. (2021): Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice. A Pilot Project in Cooperation with Tirol Kliniken GmbH & KAGes. HTA-Projektbericht 126.

Goetz, G. and Walter, M. and Wohlhöfner, K. and Wittenberg, H. and Saal, S. and Stephan, K.M. and Dohle, C. (2021): Robotics and functional electrical stimulation for stroke rehabilitation. HTA-Projektbericht 128.

Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

Grössmann, N. (2021): Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis. Update April 2021. Oncology Fact Sheet Nr. 33.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.

Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Update April 2021. Oncology Fact Sheet Nr. 35.

Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.

Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.

Grössmann, N. (2021): Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL). Update August 2021. Oncology Fact Sheet Nr. 44.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 45.

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Update August 2021. Oncology Fact Sheet Nr. 46.

Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2021): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Update February 2021. Oncology Fact Sheet Nr. 13.

Grössmann, N. (2021): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 15.

Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update February 2021. Oncology Fact Sheet Nr. 16.

Grössmann, N. (2021): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 17.

Grössmann, N. (2021): Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Update February 2021. Oncology Fact Sheet Nr. 18.

Grössmann, N. (2021): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 19.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.

Grössmann, N. (2021): Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 22.

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

Grössmann, N. (2021): Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 24.

Grössmann, N. (2021): Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL). Update February 2021. Oncology Fact Sheet Nr. 25.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. (2021): Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 29.

Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.

Grössmann, N. (2021): Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM). Update August 2021. Oncology Fact Sheet Nr. 43.

Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.

Grössmann, N. (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021. Oncology Fact Sheet Nr. 31.

Grössmann, N. (2020): Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Update February 2021. Oncology Fact Sheet Nr. 28.

Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.

Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Update July 2020. Oncology Fact Sheet Nr. 4.

Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.

Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.

Grössmann, N. and Wild, C. (2020): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003.

Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.

Huić, M. (2021): Bamlanivimab monotherapy and as combination therapy (with Etesevimab) for Covid-19. AIHTA Policy Brief 009.

Huić, M. and Swiss Network for HTA, (SNHTA) (2021): Combination therapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of Covid-19. AIHTA Policy Brief 008.

Jeindl, R. and Goetz, G. (2021): Percutaneous left ventricular assist devices: micro-axial flow pumps. Decision Support Document 124.

Jeindl, R. and Wild, C. (2020): Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples. HTA-Projektbericht 134.

Kheder, M. and Vandepeer, M. and Forel, D. and Tivey, D. (2021): Triphasic biomaterial for augmentation of the osteoporotic femoral neck. Decision Support Document 126.

Reinsperger, I. (2021): Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence. AIHTA Policy Brief 005.

Sehic, O. (2021): Sponsoring of patient initiatives in Austria. Update of the Systematic Analyses 2014 to 2018. AIHTA Policy Brief 007.

Sehic, O. and Wild, C. (2021): Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017. AIHTA Policy Brief 010.

Semlitsch, T. and Jeitler, K. and Zipp, C. and Krenn, C. and Horvath, K. and Zens, Y. and Hausner, E. and Sauerland, S. and Störchel, M. and Sturtz, S. and Varela Lema, L. and Paz Valiñas, L. and Puñal Riobóo, J. and Cantero Muñoz, P. and Faraldo Vallés, M.J. (2020): Lung cancer screening in risk groups. HTA-Projektbericht 132a.

Walter, M. and Gassner, L. (2021): Liposuction for surgical therapy of lipoedema. Decision Support Document 125.

Walter, M. and Strohmaier, C. (2020): Genetic Testing in the Context of Familial Hypercholesterolaemia Management. HTA-Projektbericht 130.

Wild, C. (2020): Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years. AIHTA Policy Brief 001.

Wild, C. and Sehic, O. (2020): Proton and carbon ion therapy - an update on indications. AIHTA Policy Brief 004.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Wohlhöfner, K. (2021): (Good) practice organisational models using real-world evidence for public funding of high prized therapies. HTA-Projektbericht 138.

Wolf, S. (2021): Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Update July 2021. Oncology Fact Sheet Nr. 38.

Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update July 2021. Oncology Fact Sheet Nr. 39.

Wolf, S. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update Juli 2021. Oncology Fact Sheet Nr. 41.

Wolf, S. (2021): Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 57.

Wolf, S. (2021): Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Oncology Fact Sheet Nr. 58.

Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Oncology Fact Sheet Nr. 59.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC). Update September 2021. Oncology Fact Sheet Nr. 52.

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021. Oncology Fact Sheet Nr. 53.

Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Update August 2021. Oncology Fact Sheet Nr. 54.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 55.

Wolf, S. (2021): Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis. Update September 2021. Oncology Fact Sheet Nr. 56.

Wolf, S. (2021): Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 47.

Wolf, S. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 48.

Wolf, S. (2021): Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 49.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021. Oncology Fact Sheet Nr. 50.

Wolf, S. and Erdos, J (2021): Epidemiology of long COVID: a preliminary report. German short version of the original KCE report. HTA-Projektbericht 135a.

Wolf, S. and Grössmann, N. (2020): Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria. HTA-Projektbericht 129.

Wolf, S. and Strohmaier, C. (2021): Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses. Decision Support Document 128.

This list was generated on Wed Sep 22 17:00:30 2021 CEST.